1-12 of 12
Shira N. Dinner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Matthew S Davids, Yesid Alvarado Valero, Catherine Diefenbach, Daniel N. Egan, Shira N. Dinner, Monzr M. Al Malki, Kebede Begna, Avyakta Kallam, Sameem Abedin, Rachel Cook, Nathalie Javidi-Sharifi, Edward Dominguez, Lu Miao, Richard G Ghalie, Alexey Danilov
Journal: Blood
Blood (2023) 142 (Supplement 1): 4286.
https://doi.org/10.1182/blood-2023-179577
Published: 2023
Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett
Journal: Blood
Blood (2023) 142 (Supplement 1): 437.
https://doi.org/10.1182/blood-2023-173742
Published: 2023
Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Selina M Luger, Zhuoxin Sun, Ryan J Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, Janis Racevckis, Hillard M. Lazarus, Jacob M. Rowe, Daniel A. Arber, Matthew J. Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent L. Wood, Yaqi Zhao, Gang Wu, Ti-Cheng Chang, Wenchao Zhang, Keith W Pratz, Shira N. Dinner, Noelle V. Frey, Steven D. Gore, Bhavana Bhatnagar, Ehab L. Atallah, Geoffrey L Uy, Deepa Jeyakumar, Tara L Lin, Cheryl L. Willman, Daniel J. DeAngelo, Elad Sharon, Richard F. Little, Harry P. Erba, Richard M Stone, Charles G. Mullighan, Mark R. Litzow, Martin S. Tallman
Journal: Blood
Blood (2023) 142 (Supplement 1): 2877.
https://doi.org/10.1182/blood-2023-189648
Published: 2023
Journal Articles

Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15)

Yvonne Efebera, Vera Jean Suman, Shira N. Dinner, Ashley E Rosko, John T Mckay, Peter Barth, Patrick Hagen, Saad Z Usmani, Paul G. Richardson, Jacob P. Laubach
Journal: Blood
Blood (2023) 142 (Supplement 1): 3340.
https://doi.org/10.1182/blood-2023-187296
Published: 2023
Journal Articles

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Jorge Cortes, Jay Yang, Sangmin Lee, Shira N. Dinner, Eunice S. Wang, Maria R. Baer, William B. Donnellan, Justin M. Watts
Journal: Blood
Blood (2023) 142 (Supplement 1): 1872.
https://doi.org/10.1182/blood-2023-187404
Published: 2023
Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6047.
https://doi.org/10.1182/blood-2023-187584
Published: 2023
Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Shukaib Arslan, Giovanni Marconi, Giovanni Martinelli, Shaun Fleming, Antonio Curti, Shira N. Dinner, James S Blachly, Matteo Giovanni Della Porta, Ashish Bajel, Tim Sauer, Martina Crysandt, Arnaud Pigneux, Lars Fransecky, Claudia D Baldus, Marina Y. Konopleva, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Patricia Cheung, Emily Rowe, Ekaterina Jahn, Ting Yu, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Nitin Jain
Journal: Blood
Blood (2023) 142 (Supplement 1): 5907.
https://doi.org/10.1182/blood-2023-179168
Published: 2023
Journal Articles

Individual-Level Social Determinants of Health (SDOH) Measures and Treatment Complications in Acute Leukemia

Eshana Shah, Ana Maria Avila Rodriguez, Jerry W Luo, Joanna Cwykiel, Tasha Chasson, Elizabeth Raigoza, Alexander Bratslavsky, Peter Doukas, Reanna Williams, Christa Jackowicz, Hyein Lee, Talha Khan, Kimberly Webb, Yasmin Abaza, Jessica K. Altman, Betina Yanez, John Quigley, Carlos Galvez, Shira N. Dinner, Kim Johnson, Madelyn Burkart, Irum Khan
Journal: Blood
Blood (2023) 142 (Supplement 1): 374.
https://doi.org/10.1182/blood-2023-189024
Published: 2023
Journal Articles

Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia

Julie B Waisbren, MD, Shira N. Dinner, MD, Irene Helenowski, PhD, Juehua Gao, MDPhD, Brandon McMahon, MD, Brady Stein, MD
Journal: Blood
Blood (2015) 126 (23): 3477.
https://doi.org/10.1182/blood.V126.23.3477.3477
Published: 2015
Journal Articles

Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

Shira N. Dinner, MD, Tamara J. Dunn, MD, Bruno C. Medeiros, MD, Steven E. Coutre, MD, Caroline Berube, MD, Jason Gotlib, M.D., M.S., Michaela Liedtke, MD
Journal: Blood
Blood (2012) 120 (21): 4027.
https://doi.org/10.1182/blood.V120.21.4027.4027
Published: 2012
Journal Articles

A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma

Tamara J. Dunn, MD, Shira N. Dinner, MD, Caroline Berube, MD, Jason Gotlib, MD, MS, Steven E. Coutre, MD, Bruno C. Medeiros, MD, Michaela Liedtke, MD
Journal: Blood
Blood (2012) 120 (21): 4304.
https://doi.org/10.1182/blood.V120.21.4304.4304
Published: 2012
Journal Articles

Biomarkers To Predict Outcome after Allogeneic Hematopoietic Cell Transplant (HCT).

Shira N. Dinner, MD, Andrew Artz, MD, MS, Masha Kocherginsky, PhD, Jodie Ulaszek, MS, Daniel Pollyea, MD, Lucy Godley, MD, PhD, Richard A. Larson, MD, Olatoysi Odenike, MD, Elizabeth Rich, MD, PhD, Wendy Stock, MD, Koen van Besien, MD, Amittha Wickrema, PhD
Journal: Blood
Blood (2007) 110 (11): 1100.
https://doi.org/10.1182/blood.V110.11.1100.1100
Published: 2007